# Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment

Study · id `cardio:ct-nct06788626` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06788626](<https://clinicaltrials.gov/study/NCT06788626>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06788626

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 390 participants.

## Technical summary

Registry record NCT06788626. Randomized; single masking; primary purpose treatment. Start 2025-02 (anticipated); primary completion 2028-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 390 participants (planned count; ClinicalTrials.gov record NCT06788626, source copy `cardio:ctgov-nct06788626-2025-01-23`, retrieved 2026-10-26)
- Planned start: 2025-02 (anticipated) (ClinicalTrials.gov record NCT06788626, source copy `cardio:ctgov-nct06788626-2025-01-23`, retrieved 2026-10-26)
- Primary completion: 2028-02 (anticipated) (ClinicalTrials.gov record NCT06788626, source copy `cardio:ctgov-nct06788626-2025-01-23`, retrieved 2026-10-26)
- Completion: 2028-02 (anticipated) (ClinicalTrials.gov record NCT06788626, source copy `cardio:ctgov-nct06788626-2025-01-23`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06788626, source copy `cardio:ctgov-nct06788626-2025-01-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06788626-2025-01-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
- Acronym: GALLOP2
- Condition: Acute Ischemic Stroke
- Condition: Large Vessel Occlusion
- Condition: Neuroprotective Drugs
- Condition: Endovascular Treatment
- Intervention (Drug): Semaglutide 0.5 mg
- Intervention (Other): Standard medical treatment
- Lead sponsor: Wei Hu
- Lead sponsor class: OTHER
- Collaborator: Chinese University of Hong Kong
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as a collaborator: Chinese University of Hong Kong (`cardio:org-chinese-university-of-hong-kong`)

## Provenance

Content hash: 163c27e84aab0a4ee6e16144287b65dd623956b7180c8eef4dab08e78a9b0e13
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
